Wells Whitney, Sc.D. received his undergraduate degree in chemistry from Harvard College in 1955 and his Masters and Doctorate degrees in Materials Science & Engineering from MIT in 1962 and 1964.
After an NSF post-doc year in Strasbourg, France, he did polymer research and product development work for Monsanto Chemical Company, Celanese Research Company, and Reprographics Materials Company.
In the early 1970s he started working for Raychem Corporation in Menlo Park, California, where he did materials research, product development and business development. Leveraging his technical expertise in the electrical and mechanical properties of materials he developed self-regulating polymeric heaters and PTC circuit protection devices, both product lines now selling many hundreds of millions of dollars. Wells has managed large, multidisciplinary R&D groups, and has done market research, strategic plan development, IP and patent drafting and analysis, and some financial analysis.
Dr. Whitney retired from Raychem in 1998, when diagnosed with stage IV Lung Cancer, and became involved part time with two start-ups, helping to raise money and to manage the growing and innovative business structures. He has served on several technical advisory boards, both for private companies and start-ups, as well as public projects. Dr. Whitney remains active on six nonprofit boards, three related to lung cancer, two related to urban planning and community involvement, and one social services agency. In addition, Wells has consulted actively for several private, for-profit companies.
Most recently Dr. Whitney, leveraging his extensive knowledge and background in all aspects of lung cancer, has been much more involved with the aforementioned lung cancer foundation and medical institute, particularly helping these organizations write strategic plans, organize their fund raising, formalize their financial reporting, and setting up appropriate staff and board positions, roles and responsibilities. His longer term role with these organizations will be to head up and lead the Scientific/Medical advisory boards aimed towards supporting innovative diagnostic and therapeutic advances for lung cancer.